title: Global pharmaceutical development and access: critical issues of ethics and equity.
abstract: The article presents global data on access to pharmaceuticals and discusses underlying barriers. Two are highly visible: pricing policies and intellectual property rights; two are less recognized: the regulatory environment and scientific and technological capacities. Two ongoing transitions influence and even distort the problem of universal access to medications: the epidemiologic transition to an increasing burden of chronic non-communicable diseases; and the growing role of biotechnology products (especially immunobiologicals) in the pharmacopeia. Examples from Cuba and Brazil are used to explore what can and should be done to address commercial, regulatory, and technological aspects of assuring universal access to medications.
authors.affiliation: Molecular Immunology Center, Havana, Cuba. lage@cim.sld.cu
authors.forename: Agustín
authors.initials: A
authors.lastname: Lage
mesh_terms: D003462:Cuba; D016527:Drug Costs / Q000941:ethics / Q000331:legislation & jurisprudence; D055808:Drug Discovery / Q000191:economics / Q000941:ethics* / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000941:ethics / Q000331:legislation & jurisprudence; D014943:Global Health; D006297:Health Services Accessibility / Q000191:economics / Q000941:ethics* / Q000331:legislation & jurisprudence; D006806:Human Rights; D006801:Humans; D010330:Patents as Topic / Q000941:ethics / Q000331:legislation & jurisprudence; D004364:Pharmaceutical Preparations / Q000191:economics / Q000600:supply & distribution*
chemical_list: D004364:Pharmaceutical Preparations